{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/phase-i-alzheimers-disease#webpage",
"url": "https://www.fortrea.com/insights/phase-i-alzheimers-disease",
"name": "Phase I Alzheimer’s Disease",
"description": "This Fortrea case study explores how Alzheimer’s disease clinical trials were managed through a patient- and site-centric approach during an early Phase I multiple dose, dose-escalation study. The study involved patients with mild cognitive impairment due to Alzheimer’s disease or mild to moderate Alzheimer’s disease and required extensive cognitive assessments, cerebrospinal fluid sampling, and repeated clinical visits throughout the trial. The case study highlights operational challenges related to patient enrollment, unpredictable cohort progression, and maintaining engagement with eligible participants across multiple dosing cohorts. Fortrea supported clinical trial operations by implementing proactive enrollment strategies, close coordination with clinical sites, and continuous communication to retain eligible patients for future cohorts while supporting efficient study progression. Through structured CNS clinical trial management and collaborative site engagement, the approach enabled accelerated enrollment timelines, earlier completion of cohorts, and timely delivery of study data to support progression into Phase II proof-of-concept development."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phase I Alzheimer’s Disease",
"item": "https://www.fortrea.com/insights/phase-i-alzheimers-disease"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/phase-i-alzheimers-disease#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/phase-i-alzheimers-disease#webpage"
},
"headline": "Alzheimer’s Disease Clinical Trials and Patient-Centric Enrollment Strategies | Fortrea Case Study",
"description": "This Fortrea case study explores how Alzheimer’s disease clinical trials were managed through a patient- and site-centric approach during an early Phase I multiple dose, dose-escalation study. The study involved patients with mild cognitive impairment due to Alzheimer’s disease or mild to moderate Alzheimer’s disease and required extensive cognitive assessments, cerebrospinal fluid sampling, and repeated clinical visits throughout the trial. The case study highlights operational challenges related to patient enrollment, unpredictable cohort progression, and maintaining engagement with eligible participants across multiple dosing cohorts. Fortrea supported clinical trial operations by implementing proactive enrollment strategies, close coordination with clinical sites, and continuous communication to retain eligible patients for future cohorts while supporting efficient study progression. Through structured CNS clinical trial management and collaborative site engagement, the approach enabled accelerated enrollment timelines, earlier completion of cohorts, and timely delivery of study data to support progression into Phase II proof-of-concept development.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2024-10/GettyImages-1053994060.webp"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-03-17",
"dateModified": "2025-03-17",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/CS_0061_NEURO_Alzheimers_1123.pdf",
"encodingFormat": "application/pdf"
}
}
]
}